VIRGINIA RETIREMENT SYSTEMS ET Al Takes $130.42 Million Position in Gilead Sciences, Inc. $GILD

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,032,295 shares of the biopharmaceutical company’s stock, valued at approximately $130,420,000. Gilead Sciences comprises about 0.8% of VIRGINIA RETIREMENT SYSTEMS ET Al’s investment portfolio, making the stock its 18th biggest holding. VIRGINIA RETIREMENT SYSTEMS ET Al owned 0.08% of Gilead Sciences at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. California State Teachers Retirement System increased its holdings in shares of Gilead Sciences by 12,498.3% during the second quarter. California State Teachers Retirement System now owns 241,168,657 shares of the biopharmaceutical company’s stock worth $30,469,248,000 after buying an additional 239,254,365 shares in the last quarter. Kintra Wealth LLC boosted its holdings in shares of Gilead Sciences by 11.1% in the 2nd quarter. Kintra Wealth LLC now owns 1,989 shares of the biopharmaceutical company’s stock worth $275,000 after acquiring an additional 198 shares in the last quarter. Saudi Central Bank boosted its holdings in shares of Gilead Sciences by 89.7% in the 2nd quarter. Saudi Central Bank now owns 86,886 shares of the biopharmaceutical company’s stock worth $10,977,000 after acquiring an additional 41,091 shares in the last quarter. Fortitude Advisory Group L.L.C. grew its position in Gilead Sciences by 7.0% during the 2nd quarter. Fortitude Advisory Group L.L.C. now owns 1,769 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 115 shares during the last quarter. Finally, Compass Financial Management LLC bought a new stake in Gilead Sciences during the 2nd quarter worth approximately $671,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV and oncology approvals broaden Gilead’s growth prospects. FDA approval of Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults on complex treatments, could strengthen the company’s HIV franchise. Separately, European approval of Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients expands Gilead’s oncology opportunity. Commercial uptake will determine the ultimate revenue impact. HIV and oncology approvals article
• Positive Sentiment: Analysts raised long-term earnings expectations. Zacks Research increased its Q1 2028 EPS estimate to $2.15, Q2 2028 to $2.31 and FY2028 to $9.66, while maintaining a “Strong Buy” rating. The revisions suggest improving confidence in Gilead’s future profitability. Gilead analyst estimates
• Positive Sentiment: An Arcus-backed cancer study reached completion. The milestone sets up a potentially important immuno-oncology catalyst, although investors will likely need to wait for efficacy and safety data before assigning significant value to the program. Arcus-backed cancer trial article
• Neutral Sentiment: Gilead continues to support income investors with a $0.82 quarterly dividend. The $3.28 annualized payout provides shareholder support, but the high payout relative to reported earnings makes future dividend growth dependent on sustained HIV cash flow and successful new-product launches. Gilead dividend article
• Neutral Sentiment: CEO Daniel O’Day sold $2.23 million of stock. The 15,000-share sale reduced his holdings by 2.53%, but it was completed under a pre-arranged Rule 10b5-1 plan, limiting its value as a bearish signal. SEC insider trading filing
• Negative Sentiment: Investors remain concerned about concentration and patent-expiration risk. Gilead’s dividend and cash generation depend heavily on its leading HIV franchise, particularly a blockbuster therapy facing a known patent expiration later in the next decade. The sharp decline in cell-therapy licensing deals also highlights uncertainty around diversification beyond HIV. Gilead dividend and patent risk article

Gilead Sciences Stock Down 0.0%

NASDAQ:GILD opened at $150.99 on Monday. The company has a market cap of $187.22 billion, a price-to-earnings ratio of -56.55 and a beta of 0.33. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The stock’s fifty day moving average price is $136.67 and its two-hundred day moving average price is $136.39. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period last year, the firm earned $2.01 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post -0.48 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Zacks Research upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 31st. Rothschild & Co Redburn decreased their target price on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Daiwa Securities Group lowered their target price on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Royal Bank Of Canada lifted their price target on Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a report on Wednesday, August 5th. Finally, Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $158.04.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares of the company’s stock, valued at $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the transaction, the insider owned 118,234 shares in the company, valued at $16,273,727.76. This represents a 19.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 105,000 shares of company stock valued at $14,495,820. 0.30% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.